Dynamic changes of immune-related molecules of peripheral blood in patients treated immunotherapy with advanced non-small cell lung cancer

Dynamic changes of immune-related molecules of peripheral blood in patients treated immunotherapy with advanced non-small cell lung cancer - ICM-2 study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042885

Enrollment

Registered

2021-01-02

Start date

2021-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with advanced non-small cell lung cancer (NSCLC: Non-Small-Cell-Lung-Cancer) scheduled to receive immunotherapy and combined immunotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced non-small-cell lung cancer Patients who are going to receive immunity checkpoint inhibitors Written informed consent is obtained from all the patients.

Exclusion criteria

Exclusion criteria: Patients having an overlap cancer with activity Patients that an doctor judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
We measured the dynamics of soluble immune checkpoint molecules, and observe clinical effect and observe toxicity, recurrence, and prognosis. Then evaluate their relevance.	—

Countries

Japan

Contacts

Public ContactNaruo Yoshimura

Tohoku Medical and Pharmaceutical University Division of Respiratory Medicine

y-naruo@sc4.so-net.ne.jp0222908850

Outcome results